Brokerages Set Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Target Price at $35.71

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) have received an average rating of “Buy” from the nine brokerages that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $35.71.

A number of brokerages recently issued reports on DAWN. JPMorgan Chase & Co. dropped their target price on Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. TD Cowen upgraded shares of Day One Biopharmaceuticals to a “strong-buy” rating in a report on Monday, November 4th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 11,245 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $16.03, for a total value of $180,257.35. Following the sale, the insider now owns 1,085,790 shares in the company, valued at $17,405,213.70. This represents a 1.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 51,745 shares of company stock worth $775,867 over the last quarter. 8.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Day One Biopharmaceuticals

A number of large investors have recently added to or reduced their stakes in the business. Franklin Resources Inc. raised its position in shares of Day One Biopharmaceuticals by 2.3% in the third quarter. Franklin Resources Inc. now owns 3,869,632 shares of the company’s stock valued at $55,336,000 after purchasing an additional 87,262 shares during the period. Geode Capital Management LLC raised its holdings in Day One Biopharmaceuticals by 10.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,432,697 shares of the company’s stock valued at $19,961,000 after acquiring an additional 136,458 shares during the period. Frazier Life Sciences Management L.P. acquired a new stake in Day One Biopharmaceuticals during the third quarter worth approximately $9,607,000. XTX Topco Ltd acquired a new stake in Day One Biopharmaceuticals during the third quarter worth approximately $178,000. Finally, Wellington Management Group LLP boosted its holdings in shares of Day One Biopharmaceuticals by 142.1% during the third quarter. Wellington Management Group LLP now owns 721,581 shares of the company’s stock worth $10,052,000 after acquiring an additional 423,543 shares during the period. Institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Stock Up 1.5 %

Shares of DAWN stock opened at $13.93 on Thursday. Day One Biopharmaceuticals has a 12-month low of $11.30 and a 12-month high of $18.07. The firm has a fifty day moving average of $14.32 and a 200-day moving average of $14.16. The company has a market capitalization of $1.40 billion, a price-to-earnings ratio of -13.52 and a beta of -1.51.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its earnings results on Wednesday, October 30th. The company reported $0.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.58. The firm had revenue of $93.76 million for the quarter, compared to the consensus estimate of $15.05 million. During the same quarter last year, the company posted ($0.54) EPS. On average, equities analysts expect that Day One Biopharmaceuticals will post -0.88 EPS for the current year.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.